SCHEMBL15788897

SCHEMBL15788897

CC(C)CSc1nc(C(=O)NC2(CC(N)=O)CS(=O)(=O)C2)ccc1C1CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 20/20 1.00
▸ CNR1 P21554 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19956482 0.88 CNR2 (0.78) CNR2CNR1
SCHEMBL19956438 0.88 CNR2 (0.78) CNR2CNR1
SCHEMBL15775143 0.81 CNR2 (0.69) CNR2CNR1
SCHEMBL15788855 0.76 CNR2 (1.00) CNR2CNR1
SCHEMBL14226408 0.75 CNR2 (1.00) CNR2CNR1
SCHEMBL15788854 0.74 CNR2 (1.00) CNR2CNR1
SCHEMBL14151962 0.74 CNR2 (0.64) CNR2CNR1
SCHEMBL15788884 0.73 CNR2 (1.00) CNR2CNR1
SCHEMBL20057372 0.69 CNR2 (0.63) CNR2CNR1
SCHEMBL17292804 0.69 CNR2 (1.00) CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3357918-A1 NOVEL PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2018-08-08 — — EP claimed
US-9522886-B2 Pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2016-12-20 — — US claimed
US-20150307452-A1 NOVEL PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-10-29 — — US claimed
EP-3357918-A1 NOVEL PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2018-08-08 — — EP disclosed
EP-3357918-A1 NOVEL PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2018-08-08 — — EP disclosed
EP-2928881-B1 NOVEL PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-03-14 — — EP disclosed
EP-2928881-B1 NOVEL PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-03-14 — — EP disclosed
US-9522886-B2 Pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2016-12-20 — — US disclosed
US-9522886-B2 Pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2016-12-20 — — US disclosed
US-9522886-B2 Pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2016-12-20 — — US disclosed
US-20150307452-A1 NOVEL PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-10-29 — — US disclosed
US-20150307452-A1 NOVEL PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-10-29 — — US disclosed
US-20150307452-A1 NOVEL PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-10-29 — — US disclosed
WO-2014086705-A1 NOVEL PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2014-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307452-A1 NOVEL PYRIDINE DERIVATIVES NDUFS6, NDUFS3, NDUFV2 CNR2 23/4885CNR1 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback